GeneDx (NASDAQ:WGS) CEO Sells 3,692 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,692 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $310,940.24. Following the sale, the chief executive officer owned 107,227 shares in the company, valued at $9,030,657.94. The trade was a 3.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, June 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $60.77, for a total transaction of $638,145.77.

GeneDx Price Performance

WGS stock traded up $1.06 during trading on Friday, reaching $85.02. The company’s stock had a trading volume of 331,591 shares, compared to its average volume of 938,779. The company has a quick ratio of 3.06, a current ratio of 3.30 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average is $74.31 and its 200-day moving average is $66.65. The company has a market capitalization of $2.54 billion, a P/E ratio of -23.36 and a beta of 1.99. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.20. The business had revenue of $114.44 million for the quarter, compared to the consensus estimate of $111.01 million. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%.During the same period in the previous year, the business earned $0.36 earnings per share. On average, research analysts expect that GeneDx Holdings Corp. will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new position in GeneDx during the 4th quarter valued at approximately $27,000. Fifth Third Bancorp purchased a new stake in shares of GeneDx during the 1st quarter worth approximately $31,000. Quarry LP raised its holdings in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares in the last quarter. Ramirez Asset Management Inc. bought a new position in shares of GeneDx during the 4th quarter valued at approximately $33,000. Finally, Greenline Wealth Management LLC bought a new position in shares of GeneDx during the 4th quarter valued at approximately $33,000. 61.72% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

WGS has been the subject of several recent analyst reports. TD Cowen restated a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Guggenheim reiterated a “buy” rating and set a $74.00 price objective (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $89.57.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.